At what stage is this treatment used?
- First-line combination and second-line monotherapy treatment of advanced (metastatic) colorectal cancer.
Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Irinotecan is PBS-subsidised as a treatment option for advanced (metastatic) colorectal cancer in patients with a WHO performance status of 2 or less. Note: In first-line usage, effectiveness and tolerance may be improved when Irinotecan is combined with an infusional 5-fluorouracil regimen (e.g. FOLFIRI).
Download the Consumer Medicine Information (CMI) for Camptosar.